Published in Curr Epidemiol Rep on December 01, 2014
Use of Prescription Drug Samples in the USA: A Descriptive Study with Considerations for Pharmacoepidemiology. Drug Saf (2016) 0.78
Are all biases missing data problems? Curr Epidemiol Rep (2015) 0.77
A review of routinely collected data studies in urology: Methodological considerations, reporting quality, and future directions. Can Urol Assoc J (2017) 0.75
Associations between the patient-centered medical home and preventive care and healthcare quality for non-elderly adults with mental illness: A surveillance study analysis. BMC Health Serv Res (2016) 0.75
Bias in analytic research. J Chronic Dis (1979) 16.40
The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol (1991) 12.76
The continuing unethical use of placebo controls. N Engl J Med (1994) 12.21
Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol (2003) 11.24
Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA (2012) 5.90
A method to automate probabilistic sensitivity analyses of misclassified binary variables. Int J Epidemiol (2005) 5.17
Correction of logistic regression relative risk estimates and confidence intervals for systematic within-person measurement error. Stat Med (1989) 5.08
Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf (2006) 4.64
Regression calibration method for correcting measurement-error bias in nutritional epidemiology. Am J Clin Nutr (1997) 3.68
Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf (2007) 3.66
Basic methods for sensitivity analysis of biases. Int J Epidemiol (1996) 3.64
Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis. Arch Intern Med (2012) 3.50
Communicating evidence for participatory decision making. JAMA (2004) 3.49
Effect of questionnaire design on recall of drug exposure in pregnancy. Am J Epidemiol (1986) 3.34
Semi-automated sensitivity analysis to assess systematic errors in observational data. Epidemiology (2003) 3.30
Multiple-imputation for measurement-error correction. Int J Epidemiol (2006) 3.13
Case series analysis of adverse reactions to vaccines: a comparative evaluation. Am J Epidemiol (1996) 2.65
Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med (2008) 2.59
Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration. Am J Epidemiol (2005) 2.55
Relative incidence estimation from case series for vaccine safety evaluation. Biometrics (1995) 2.55
Logistic regression when the outcome is measured with uncertainty. Am J Epidemiol (1997) 2.49
Proper interpretation of non-differential misclassification effects: expectations vs observations. Int J Epidemiol (2005) 2.34
Evidence of sample use among new users of statins: implications for pharmacoepidemiology. Med Care (2014) 2.22
Mismeasurement and the resonance of strong confounders: uncorrelated errors. Am J Epidemiol (1996) 2.21
On the nondifferential misclassification of a binary confounder. Epidemiology (2012) 2.14
Invited Commentary: Causal diagrams and measurement bias. Am J Epidemiol (2009) 2.06
Identifying patient preferences for communicating risk estimates: a descriptive pilot study. BMC Med Inform Decis Mak (2001) 1.88
Estimating and correcting for confounder misclassification. Am J Epidemiol (1989) 1.80
Exposure-time-varying hazard function ratios in case-control studies of drug effects. Pharmacoepidemiol Drug Saf (2006) 1.73
An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients. Med Care (2008) 1.63
Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol (1994) 1.61
Bias due to non-differential misclassification of polytomous confounders. J Clin Epidemiol (1993) 1.59
Adjustments for unmeasured confounders in pharmacoepidemiologic database studies using external information. Med Care (2007) 1.56
Nonexperimental comparative effectiveness research using linked healthcare databases. Epidemiology (2011) 1.50
Bayesian sensitivity analysis for unmeasured confounding in observational studies. Stat Med (2007) 1.44
Validation data-based adjustments for outcome misclassification in logistic regression: an illustration. Epidemiology (2011) 1.35
Sensitivity analysis of misclassification: a graphical and a Bayesian approach. Ann Epidemiol (2006) 1.30
Completeness of prescription information in US commercial claims databases. Pharmacoepidemiol Drug Saf (2013) 1.23
Characteristics of patients with primary non-adherence to medications for hypertension, diabetes, and lipid disorders. J Gen Intern Med (2011) 1.22
Bayesian methods for correcting misclassification: an example from birth defects epidemiology. Epidemiology (2009) 1.19
Is probabilistic bias analysis approximately Bayesian? Epidemiology (2012) 1.16
Estimation using all available covariate information versus a fixed look-back window for dichotomous covariates. Pharmacoepidemiol Drug Saf (2013) 1.15
Accounting for misclassified outcomes in binary regression models using multiple imputation with internal validation data. Am J Epidemiol (2013) 1.06
A null association between smoking during pregnancy and breast cancer using Massachusetts registry data (United States). Cancer Causes Control (2003) 0.98
Comparison of bias analysis strategies applied to a large data set. Epidemiology (2014) 0.95
Intracranial hemorrhage mortality in atrial fibrillation patients treated with dabigatran or warfarin. Stroke (2014) 0.94
Mini-Sentinel's systematic reviews of validated methods for identifying health outcomes using administrative data: summary of findings and suggestions for future research. Pharmacoepidemiol Drug Saf (2012) 0.93
Correcting for exposure misclassification using survival analysis with a time-varying exposure. Ann Epidemiol (2012) 0.92
Autism spectrum disorder, flea and tick medication, and adjustments for exposure misclassification: the CHARGE (CHildhood Autism Risks from Genetics and Environment) case-control study. Environ Health (2014) 0.88
Propensity score calibration in the absence of surrogacy. Am J Epidemiol (2012) 0.86
Quantifying the impact of drug exposure misclassification due to restrictive drug coverage in administrative databases: a simulation cohort study. Value Health (2011) 0.85
Analyzing partially missing confounder information in comparative effectiveness and safety research of therapeutics. Pharmacoepidemiol Drug Saf (2012) 0.85
Accounting for outcome misclassification in estimates of the effect of occupational asbestos exposure on lung cancer death. Am J Epidemiol (2013) 0.84
Adjusting for multiple-misclassified variables in a study using birth certificates. Ann Epidemiol (2013) 0.83
Variation in the days supply field for osteoporosis medications in Ontario. Arch Osteoporos (2013) 0.83
Efficacy and safety evaluation of intensive statin therapy in older patients with coronary heart disease: a systematic review and meta-analysis. Eur J Clin Pharmacol (2013) 0.82
Prevalence of unclaimed prescriptions at military pharmacies. J Manag Care Pharm (2008) 0.81
Consumption of dairy products and colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). PLoS One (2013) 0.81
Bias Correction Methods for Misclassified Covariates in the Cox Model: comparison offive correction methods by simulation and data analysis. J Stat Theory Pract (2013) 0.80
Evaluating the introduction of a computerized prior-authorization system on the completeness of drug exposure data. Pharmacoepidemiol Drug Saf (2013) 0.77
Risk of colorectal cancer after initiation of orlistat: matched cohort study. BMJ (2013) 0.76
Estimating incidence rates with misclassified disease status: a likelihood-based approach, with application to hepatitis C virus. Int J Infect Dis (2012) 0.76